Full Text
EE430 Cost-Effectiveness of Tremelimumab or Tremelimumab in Combination with Durvalumab Vs Durvalumab As Treatment of Advanced Hepatocellular Carcinoma

Abstract

Authors

T. Tang L. Shi

Back to Volume 26, Supplemental Issue 6S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×